A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats

• Main Authors: Teruhiko Mizumoto (Author), Yutaka Kakizoe (Author), Terumasa Nakagawa (Author), Yasunobu Iwata (Author), Yoshikazu Miyasato (Author), Kohei Uchimura (Author), Masataka Adachi (Author), Qinyuan Deng (Author), Manabu Hayata (Author), Jun Morinaga (Author), Taku Miyoshi (Author), Yuichiro Izumi (Author), Takashige Kuwabara (Author), Yoshiki Sakai (Author), Kimio Tomita (Author), Kenichiro Kitamura (Author), Masashi Mukoyama (Author)
• Format: Book
• Published: Elsevier, 2021-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Metabolic syndrome (MetS) is associated with chronic kidney disease and proteinuria. Previously, we reported that a synthetic serine protease inhibitor, camostat mesilate (CM), mitigated hypertension and proteinuria in rodent disease models. The present study evaluated the anti-hypertensive and anti...